Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Phase 2 for Stress & Mood Disorders Set for 1Q 2026

Reuters08-21

Protagenic <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Advances PT00114 into Multiple-Dose Phase 1 Trial; Phase 2 for Stress & Mood Disorders Set for 1Q 2026

Protagenic Therapeutics Inc. has announced the advancement of its investigational therapy, PT00114, into a multiple-dose Phase 1 clinical trial. The biopharmaceutical company, known for developing novel neuro-active peptide therapies, expects to complete dosing by the end of August 2025. Topline safety data is anticipated by the end of September 2025, which will support the transition into Phase 2 efficacy studies scheduled for the first quarter of 2026. PT00114, based on Teneurin C-terminus Associated Peptide $(TCAP)$, aims to modulate the brain's responses to stress, offering a new approach to treating stress-related and mood disorders such as anxiety, depression, addiction, and PTSD. Results from the multiple-dose Phase 1 trial have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1063654) on August 21, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2561467145?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-21 20:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2561467145","market":"nz","top_or_hot":-1,"title":"Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Phase 2 for Stress & Mood Disorders Set for 1Q 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Protagenic <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Advances PT00114 into Multiple-Dose Phase 1 Trial; Phase 2 for Stress &amp; Mood Disorders Set for 1Q 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PTIX\">Protagenic Therapeutics Inc</a>. has announced the advancement of its investigational therapy, PT00114, into a multiple-dose Phase 1 clinical trial. The biopharmaceutical company, known for developing novel neuro-active peptide therapies, expects to complete dosing by the end of August 2025. Topline safety data is anticipated by the end of September 2025, which will support the transition into Phase 2 efficacy studies scheduled for the first quarter of 2026. PT00114, based on Teneurin C-terminus Associated Peptide <a href=\"https://laohu8.com/S/TCAP\">$(TCAP)$</a>, aims to modulate the brain's responses to stress, offering a new approach to treating stress-related and mood disorders such as anxiety, depression, addiction, and PTSD. Results from the multiple-dose Phase 1 trial have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1063654) on August 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Phase 2 for Stress & Mood Disorders Set for 1Q 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProtagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Phase 2 for Stress & Mood Disorders Set for 1Q 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-21 20:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Protagenic <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Advances PT00114 into Multiple-Dose Phase 1 Trial; Phase 2 for Stress &amp; Mood Disorders Set for 1Q 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PTIX\">Protagenic Therapeutics Inc</a>. has announced the advancement of its investigational therapy, PT00114, into a multiple-dose Phase 1 clinical trial. The biopharmaceutical company, known for developing novel neuro-active peptide therapies, expects to complete dosing by the end of August 2025. Topline safety data is anticipated by the end of September 2025, which will support the transition into Phase 2 efficacy studies scheduled for the first quarter of 2026. PT00114, based on Teneurin C-terminus Associated Peptide <a href=\"https://laohu8.com/S/TCAP\">$(TCAP)$</a>, aims to modulate the brain's responses to stress, offering a new approach to treating stress-related and mood disorders such as anxiety, depression, addiction, and PTSD. Results from the multiple-dose Phase 1 trial have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1063654) on August 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PTIX","symbol_name":"Protagenic Therapeutics Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250821:nNDL4XBm4H:1","article_id":"2561467145","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2561467145","pubTimestamp":1755778336,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Phase 2 for Stress & Mood Disorders Set for 1Q 2026. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire  on August 21, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PTIX":"Protagenic Therapeutics Inc","BK4139":"生物科技"},"translate_title":"Protagenic Therapeutics将PT00114推进至多剂量1期试验；压力和情绪障碍第二阶段定于2026年第一季度进行","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTIX":0.9},"content_text":"Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Phase 2 for Stress & Mood Disorders Set for 1Q 2026\n    \n\nProtagenic Therapeutics Inc. has announced the advancement of its investigational therapy, PT00114, into a multiple-dose Phase 1 clinical trial. The biopharmaceutical company, known for developing novel neuro-active peptide therapies, expects to complete dosing by the end of August 2025. Topline safety data is anticipated by the end of September 2025, which will support the transition into Phase 2 efficacy studies scheduled for the first quarter of 2026. PT00114, based on Teneurin C-terminus Associated Peptide $(TCAP)$, aims to modulate the brain's responses to stress, offering a new approach to treating stress-related and mood disorders such as anxiety, depression, addiction, and PTSD. Results from the multiple-dose Phase 1 trial have not yet been presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1063654) on August 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2561467145","isCrawlerRequest":true}